Skip to main content

Table 5 Percent inhibition of the combined NRG/EGF/HGF cocktail signal with c-Met inhibitors against each listed pan-HER inhibitor on patient sample R66

From: Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy

Pan-HER inhibitors

Average inhibition (%) w/ different c-Met inhibitors

Poziotinib

100 (n = 3)

Neratinib

100 (n = 6)

Ibrutinib

99 (n = 6)

Dacomitinib

100 (n = 6)

Sapitinib

98 (n = 6)

Lapatinib

80 (n = 6)

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X